Adicet Bio, Inc.

$7.76+7.03%(+$0.51)
TickerSpark Score
58/100
Mixed
80
Valuation
20
Profitability
55
Growth
84
Health
50
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACET research report →

52-Week Range15% of range
Low $6.01
Current $7.76
High $17.44

Companywww.adicetbio.com

Adicet Bio, Inc. , a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients.

CEO
Chen Schor
IPO
2018
Employees
152
HQ
Boston, MA, US

Price Chart

-35.28% · this period
$16.64$11.38$6.11May 20Nov 18May 20

Valuation

Market Cap
$72.54M
P/E
-0.77
P/S
0.00
P/B
0.60
EV/EBITDA
-0.48
Div Yield
0.00%

Profitability

Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
-80.35%
ROIC
-73.91%

Growth & Income

Revenue
$0 · 0.00%
Net Income
$-116,803,000 · 0.27%
EPS
$-16.95 · 20.35%
Op Income
$-122,114,000
FCF YoY
-3.73%

Performance & Tape

52W High
$17.44
52W Low
$6.01
50D MA
$7.46
200D MA
$9.57
Beta
1.51
Avg Volume
118.87K

Get TickerSpark's AI analysis on ACET

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Apr 27, 26RA CAPITAL MANAGEMENT, L.P.other250,000
Apr 27, 26RA CAPITAL MANAGEMENT, L.P.other250,000
Feb 20, 26RA CAPITAL MANAGEMENT, L.P.buy74,751
Feb 19, 26RA CAPITAL MANAGEMENT, L.P.buy74,268
Feb 18, 26RA CAPITAL MANAGEMENT, L.P.buy74,577
Feb 17, 26RA CAPITAL MANAGEMENT, L.P.other0
Feb 17, 26RA CAPITAL MANAGEMENT, L.P.other1,152,833
Apr 7, 26ORBIMED ADVISORS LLCsell29,319
Apr 7, 26ORBIMED ADVISORS LLCsell2,400
Apr 8, 26ORBIMED ADVISORS LLCsell32,523

Our ACET Coverage

We haven't published any research on ACET yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate ACET Report →

Similar Companies